These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14666909)

  • 1. Lexiva (fosamprenavir) approved.
    AIDS Treat News; 2003 Oct; (395):2. PubMed ID: 14666909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA grants approval to fosamprenavir calcium.
    AIDS Alert; 2004 Jan; 19(1):11-2. PubMed ID: 14974421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA notifications. FDA approves NDA for Lexiva.
    AIDS Alert; 2007 Dec; 22(12):142. PubMed ID: 18415960
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA approves Lexiva.
    IAPAC Mon; 2003 Nov; 9(11):280. PubMed ID: 14989187
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA notifications. FDA approves new formulation of Lexiva.
    AIDS Alert; 2007 Aug; 22(8):90-1. PubMed ID: 17768778
    [No Abstract]   [Full Text] [Related]  

  • 6. Lower dose of ritonavir approved for use with fosamprenavir.
    Sax PE
    AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA notifications. Fosamprenavir label is updated.
    AIDS Alert; 2008 Feb; 23(2):21-2. PubMed ID: 18578033
    [No Abstract]   [Full Text] [Related]  

  • 8. Amprenavir approved.
    STEP Perspect; 1999; 99(2):8. PubMed ID: 11366753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosamprenavir: drug development for adherence.
    Hester EK; Chandler HV; Sims KM
    Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amprenavir, new protease inhibitor, approved.
    James JS
    AIDS Treat News; 1999 May; (No 318):1-3. PubMed ID: 11366454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug approval.
    AIDS Policy Law; 1999 Apr; 14(8):12. PubMed ID: 11366532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amprenavir approved.
    AIDS Patient Care STDS; 1999 Jul; 13(7):438. PubMed ID: 10870601
    [No Abstract]   [Full Text] [Related]  

  • 13. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agenerase approved by FDA.
    Gaylord G
    Posit Living; 1999 May; 8(4):6. PubMed ID: 12492061
    [No Abstract]   [Full Text] [Related]  

  • 15. Amprenavir (Agenerase) receives FDA approval. Food and Drug Administration.
    Highleyman L
    BETA; 1999 Apr; 12(2):3. PubMed ID: 11366693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
    Wire MB; Baker KL; Jones LS; Shelton MJ; Lou Y; Thomas GJ; Berrey MM
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1578-80. PubMed ID: 16569890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA approves an AIDS drug from Vertex. Food and Drug Administration.
    Newsline People AIDS Coalit N Y; 1999; ():32. PubMed ID: 11367345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HIV agents. Saquinavir with fosamprenavir.
    TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
    [No Abstract]   [Full Text] [Related]  

  • 20. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    Kurowski M; Walli RK; Breske A; Kruse G; Stocker H; Banik N; Richter H; Mazur D
    AIDS; 2007 Jun; 21(10):1368-70. PubMed ID: 17545717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.